KYMR Similar Chart Price Prediction
The price of KYMR is predicted to go up -23.49%, based on the high correlation periods with API. The similarity of these two price pattern on the periods is 93.13%.
KYMR
API
Down: -23.49%Similarity: 93.13%
KYMR Revenue Forecast
KYMR EPS Forecast
KYMR FAQs
What is bull’s view on KYMR?
What is bear's view on KYMR?
What is KYMR revenue forecast for next quarter？
What is KYMR eps forecast for next quarter？
KYMR Analyst's Forecast
Jeet Mukherjee
BTIG
Strong Buy
2024-12-10
Price Target
$60
Upside
+33.19%
BTIG analyst Jeet Mukherjee initiated coverage of Kymera Therapeutics with a Buy rating and $60 price target. The company is a differentiated player in the degrader field going after immunology & inflammation targets where removal of critical proteins and their scaffolding function could provide greater efficacy that better reflects biologics rather than small molecule inhibitors, the analyst tells investors in a research note. BTIG adds that it sees STAT6 degrader, KT-621, having the potential for Dupixent-like efficacy, with Phase 1 HV data coming in the first half of FY25, while Kymera's TYK2 degrader KT-295 could differentiate from TYK2 inhibitors, with Phase 1 data coming in the second half of FY25.
Sudan Loganathan
Stephens & Co.
Buy
2024-11-18
Price Target
$65
Upside
+53.27%
Jeff Jones
Oppenheimer
Buy
2024-09-27
Price Target
$52 → $56
Upside
+15.01%
